Opus Genetics (IRD) Invested Capital (2019 - 2026)

Opus Genetics (IRD) posted quarterly Invested Capital of $215000.0 for Q1 2022, down 60.04% quarter-over-quarter from $538000.0 in Q4 2021.

Analysis

Opus Genetics (IRD) Invested Capital (2019 - 2026) Analysis & Trends

Opus Genetics (IRD) has reported Invested Capital for 2 consecutive years, with $215000.0 the latest figure, recorded in Q1 2022.

In Q1 2022, Invested Capital changed N/A year-over-year to $215000.0; the TTM figure through Dec 2022 stood at $215000.0 (down 60.04% YoY), while the FY2021 annual figure was $538000.0, changed N/A from the prior year.
Invested Capital fell to $215000.0 in Q1 2022 per IRD's latest filing, from $538000.0 in the prior quarter.
Across five years, Invested Capital topped out at $538000.0 in Q4 2021 and bottomed at $215000.0 in Q1 2022.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Invested Cap. (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	33.70 Bn
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	-
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	7.35 Bn
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	6.25 Bn
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	-
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	19.13 Bn
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	1.30 Bn
10	Opus Genetics	446.86 Mn	358.05 Mn	-	285.28 Mn

Historic Data

Download Data